Free Trial

Amalgamated Bank Purchases 5,095 Shares of Teleflex Incorporated (NYSE:TFX)

Teleflex logo with Medical background

Amalgamated Bank increased its position in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 56.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,046 shares of the medical technology company's stock after purchasing an additional 5,095 shares during the period. Amalgamated Bank's holdings in Teleflex were worth $1,941,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Headlands Technologies LLC acquired a new position in Teleflex during the fourth quarter worth $29,000. MassMutual Private Wealth & Trust FSB increased its holdings in Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after buying an additional 100 shares during the period. Whipplewood Advisors LLC raised its position in Teleflex by 7,700.0% in the first quarter. Whipplewood Advisors LLC now owns 234 shares of the medical technology company's stock worth $32,000 after purchasing an additional 231 shares in the last quarter. True Wealth Design LLC boosted its stake in Teleflex by 62.3% in the 4th quarter. True Wealth Design LLC now owns 271 shares of the medical technology company's stock valued at $48,000 after buying an additional 104 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of Teleflex in the 4th quarter worth about $62,000. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Stock Performance

Shares of NYSE TFX traded down $0.81 during midday trading on Wednesday, hitting $118.87. 452,191 shares of the company's stock were exchanged, compared to its average volume of 633,071. Teleflex Incorporated has a 12 month low of $115.94 and a 12 month high of $249.91. The company's 50 day moving average price is $122.41 and its 200 day moving average price is $144.75. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $5.25 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 1.87 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.88 by $0.03. The firm had revenue of $700.67 million for the quarter, compared to the consensus estimate of $699.37 million. Teleflex had a net margin of 4.96% and a return on equity of 14.73%. The company's quarterly revenue was down 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $3.21 earnings per share. As a group, analysts predict that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.14%. The ex-dividend date was Tuesday, May 20th. Teleflex's payout ratio is 42.90%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TFX. Wells Fargo & Company cut their price objective on Teleflex from $146.00 to $137.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Wall Street Zen cut shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Royal Bank Of Canada lowered their price target on Teleflex from $150.00 to $145.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Morgan Stanley decreased their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a research note on Monday, May 5th. Finally, Mizuho set a $155.00 price objective on shares of Teleflex in a research report on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Teleflex presently has an average rating of "Hold" and a consensus target price of $164.63.

Get Our Latest Research Report on TFX

Teleflex Profile

(Free Report)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Read More

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Should You Invest $1,000 in Teleflex Right Now?

Before you consider Teleflex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.

While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines